Development Milestone: Synairgen announces patient recruitment completion of their Phase 3 COVID-19 Study Featured Image

Development Milestone: Synairgen announces patient recruitment completion of their Phase 3 COVID-19 Study

12 Nov 21

Download as PDF

tranScrip is delighted to announce that Synairgen have completed the recruitment of their randomised, double-blind, placebo-controlled Phase 3 trial evaluating inhaled formulation of interferon-beta for the treatment of hospitalised COVID-19 patients.

Dr Marcin Mankowski, tranScrip’s Managing Partner, commented: “tranScrip has provided a range of specialist support services to Synairgen for over 10 years and has been heavily involved in their COVID-19 programme since the beginning. We are thrilled that the study achieved its enrolment goal and will be looking to publish the results in early 2022. Inhaled formulation of interferon may become an important addition to the therapeutic armamentarium in the fight against SARS-CoV-2 infection”.

For further reading, please visit Synairgen Press Release

Notes for Editors

About tranScrip

tranScrip is a global leader in the Specialist Service Sector, supporting pharma & biotech companies and investors from Europe, North America and Asia. tranScrip’s senior in-house multi-disciplinary teams are unique, with high-level expertise and deep functional competencies that deliver both strategic leadership and operational support to clients, covering strategic development, medical, regulatory, drug safety and commercial services across a multitude of therapy areas from pre-clinical through to commercialisation. tranScrip forms long-standing and successful partnerships with clients, a beneficial approach that maximises opportunities, reduces risk, creates value and accomplishes strategic goals.

About Synairgen

Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. Granted Fast Track status from the US Food and Drug Administration (FDA) and deemed an Urgent Public Health study by the UK’s National Institute for Health Research (NIHR), Synairgen’s Phase III clinical programme is currently evaluating nebulised SNG001 in patients across 17 countries. In a Phase II trial in hospitalised COVID-19 patients, SNG001 demonstrated a greater than twofold chance of recovery to ‘no limitation of activities’ versus placebo.


Synairgen Press Release

Contact our team of experts

Our physicians, scientists and service experts can help to maximise the value of your products. Whatever your project requires, we have the people to meet your needs.